Grožio Medicina - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | - | 1,551,240 | 1,434,532 | 479,261 | 111,505 | 398,497 | 354,619 | 97,043 |
| Profit before tax | -215,869 | 3,380,524 | 382,840 | 319,059 | 47,643 | 43,986 | 189,027 | 99,256 |
| Net profit | -215,869 | 3,334,017 | 365,519 | 315,791 | 45,112 | 41,999 | 167,097 | 82,209 |
| Equity | -1,253,947 | 1,848,070 | 1,889,589 | 1,521,760 | 1,576,491 | 1,618,490 | 1,785,587 | 1,867,796 |
| Liabilities | 3,488,917 | 2,718,409 | 1,393,456 | 2,590,509 | 3,840,147 | 3,519,317 | 3,373,517 | 2,970,986 |
| Non-current assets | 1,078,613 | 1,665,192 | 106,198 | 246,075 | 293,836 | 283,757 | 521,451 | 507,092 |
| Current assets | 1,157,532 | 2,900,306 | 3,176,201 | 3,864,825 | 5,120,917 | 4,852,936 | 4,637,653 | 4,331,690 |
| Total assets | 2,236,145 | 4,565,498 | 3,282,399 | 4,110,900 | 5,414,753 | 5,136,693 | 5,159,104 | 4,838,782 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 945 | 145 | 29,533 |
|
Financial indicators
|
||||||||
| Revenue change y/y | - | - | -7.5% | -66.6% | -76.7% | +257.4% | -11.0% | -72.6% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -9.7% | 73.0% | 11.1% | 7.7% | 0.8% | 0.8% | 3.2% | 1.7% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | 180.4% | 19.3% | 20.8% | 2.9% | 2.6% | 9.4% | 4.4% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | 214.9% | 25.5% | 65.9% | 40.5% | 10.5% | 47.1% | 84.7% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | 217.9% | 26.7% | 66.6% | 42.7% | 11.0% | 53.3% | 102.3% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | 1.5 | 0.7 | 1.7 | 2.4 | 2.2 | 1.9 | 1.6 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | 1,551,240 | 1,434,532 | 479,261 | 111,505 | 398,497 | 354,619 | 97,043 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Grožio Medicina - Social security debts
The amount of overdue SODRA debt for the company Grožio Medicina as of the last working day is: 61 €
| From | To | Debt, € |
|---|---|---|
| 2026-09-16 | 2026-09-16 | 60.90 |
| 2026-08-26 | 2026-08-29 | 61.22 |
| 2026-08-23 | 2026-08-23 | 61.22 |
| 2026-08-19 | 2026-08-19 | 61.22 |
| 2026-05-17 | 2026-05-25 | 60.81 |
| 2026-01-16 | 2026-01-27 | 27.78 |
Grožio Medicina - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-12-18 | 2025-12-22 | 4315.53 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Grožio Medicina, UAB (code 300997578) is a Private Limited Liability Company engaged in buying and selling of own real estate. In 2025, the company generated revenue of €97.0K and net profit of €82.2K, compared with €354.6K revenue and €167.1K net profit in 2024 and €398.5K revenue and €42.0K net profit in 2023. Revenue therefore declined sharply over the last two years, while profitability strengthened materially, lifting the 2025 net profit margin to 84.7%. The balance sheet remained sizeable, with total assets of €4.84M, equity of €1.87M and liabilities of €2.97M at the end of 2025. Compared with 2024, assets and liabilities both decreased, while equity continued to rise. The latest ratios indicate moderate returns on the equity base, with ROE at 4.4% and ROA at 1.7%, and leverage at 1.59 times equity. Asset turnover remained very low, reflecting limited revenue generation relative to the asset base. Revenue per employee was €97.0K and profit per employee €82.2K in 2025.